Merus NV

NASDAQ:MRUSUnited States

May 29, 2024

Show headlines and story abstract

• *DJ Merus Announces Pricing of Upsized Public Offering of Common Shares, from 9:35PM ET on Wednesday May 29, 2024 by Dow Jones

  9:35PM ET on Wednesday May 29, 2024 by Dow Jones
  Companies Mentioned: MRUS

• Merus Announces Pricing of Upsized Public Offering of Common Shares, from 9:30PM ET on Wednesday May 29, 2024 by GlobeNewswire

  9:30PM ET on Wednesday May 29, 2024 by GlobeNewswire
  Companies Mentioned: MRUS

• Merus Announces Pricing of Upsized Public Offering of Common Shares, from 9:30PM ET on Wednesday May 29, 2024 by Dow Jones

  9:30PM ET on Wednesday May 29, 2024 by Dow Jones
  Companies Mentioned: MRUS
  
  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the completion of the proposed offering, the anticipated gross proceeds from the offering and our intended use of any proceeds from the offering. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics(R) , Triclonics(R) and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the global instability caused by the Russia, Ukraine conflict, and conflict in the Middle East; we may not identify suitable Biclonics(R) or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
  

• BofA Securities Adjusts Merus Price Target to $80 From $61, Maintains Buy Rating, from 8:52AM ET on Wednesday May 29, 2024 by MT Newswires

  8:52AM ET on Wednesday May 29, 2024 by MT Newswires
  Companies Mentioned: MRUS
  08:52 AM EDT, 05/29/2024 (MT Newswires) -- Merus N.V (MRUS) has an average rating of Buy and price targets ranging from $54 to $93, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major b...